{"nctId":"NCT01265667","briefTitle":"Trial of CF101 to Treat Patients With Psoriasis","startDateStruct":{"date":"2011-07"},"conditions":["Plaque Psoriasis"],"count":293,"armGroups":[{"label":"CF101 2 mg","type":"EXPERIMENTAL","interventionNames":["Drug: CF101"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"CF101","otherNames":["IB-MECA"]},{"name":"Placebo","otherNames":["Dummy pills"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, 18 to 80 years of age, inclusive\n* Diagnosis of moderate-to-severe chronic plaque-type psoriasis with body surface area involvement ≥10%\n* Duration of psoriasis of at least 6 months\n* Physician global assessment (PGA) ≥3\n* Candidate for systemic treatment or phototherapy for psoriasis\n* Electrocardiogram (ECG) is normal\n* Females of child-bearing potential must have a negative serum pregnancy test\n* Females of child-bearing potential must be willing to use 2 methods of contraception\n* Ability to complete the study in compliance with the protocol\n* Ability to understand and provide written informed consent.\n\nExclusion Criteria:\n\n* Erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis\n* Treatment with systemic retinoids, corticosteroids, or immunosuppressive agents within 4 weeks of the Baseline visit\n* Treatment with high potency topical corticosteroids, keratolytics, or coal tar within 2 weeks of the Baseline visit\n* Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit\n* Treatment with a biological agent within a period of time equal to 5 times its circulating half-life\n* Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit\n* Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal\n* Liver aminotransferase levels greater than the laboratory's upper limit of normal\n* Significant acute or chronic medical or psychiatric illness\n* Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to Screening visit.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects Achieving Psoriasis Area and Severity Index (PASI) 75 at 12 Weeks","description":"Achievement of PASI 75 indicates a 75% reduction in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Achieving PGA of 0 or 1","description":"PGA is a physician's assessment of the severity of disease based on a 6-point scale (score of 0 = clear and 5 = very severe)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Numberof Patients Achieving Psoriasis Area and Severity (PASI) Score of 50 or 75","description":"Achievement of PASI 50 or 75 indicates a 50% and 75% reduction respectively in the PASI score, which ranges from 0 (no disease) to 72 (maximal disease)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Nature and Frequency of Adverse Events","description":"Assessment of safety of CF101 in this patient population by gathering adverse event data based on history, vital signs, physical examination, and laboratory data","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":145},"commonTop":["Urinary tract infection","Nasopharyngitis","Diarrhoea","Headache","Haematuria"]}}}